Pharmacy Times

JANUARY 16, 2023

If patients attend their discharge appointments at pharmacist-led heart failure transition of care clinics, they are less likely to be readmitted to the hospital within 30 days.

Hospitals 48

Hospitals 48

STAT

OCTOBER 9, 2023

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

290

290

STAT

JANUARY 2, 2024

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: In December, Vertex Pharmaceuticals announced results from a mid-stage clinical trial showing its experimental, non-opioid drug reduced pain in people with diabetes who have chronic pain.

Diabetes 240

Diabetes 240

STAT

MAY 20, 2023

An early-stage drug for a heart disease called ATTR-CM showed potential to reverse disease progression, opening up a new way of attacking the condition as existing drugs have been designed to only slow or stall the disease. Continue to STAT+ to read the full story…

261

261

Express Pharma

MARCH 25, 2024

The agreement includes Cardior’s lead compound CDR132L, currently in phase 2 clinical development for the treatment of heart failure. Claudia Ulbrich, MD, CEO and co-founder of Cardior said, “This acquisition is a reflection of CDR132L’s transformative potential as a disease-modifying therapy for heart failure.

Compounding 100

Compounding Communication 100

STAT

DECEMBER 6, 2023

In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Diabetes 265

Diabetes Drug Pricing 265

STAT

AUGUST 30, 2023

Founded in 2015, Biofourmis has been developing a dizzying array of tech-enabled care offerings, including home-based care services for hospitals, clinical trials support for biopharma companies, and a pipeline of software-based interventions for heart failure and other conditions.

Hospitals 305

Hospitals 305

LifeProNow

MAY 8, 2023

May 09, 2023: “AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF.

Diabetes 130

Diabetes 130

Pharmacy Times

SEPTEMBER 19, 2023

An average patient with heart failure can take up to 6 medications for guideline-directed medical therapy; however, they may have other comorbidities that require pharmacologic management.

49

49

European Pharmaceutical Review

MAY 19, 2023

Final draft guidance has been published for the first National Institute for Health and Care Excellence (NICE)-recommended treatment for symptomatic chronic heart failure with preserved or mildly reduced ejection fraction. The study enrolled 6,263 randomised patients. This was reported as 16.4 percent in the dapagliflozin group and 19.5

Hospitals 102

Hospitals 102

pharmaphorum

AUGUST 8, 2022

A study of a mobile health app used to support patients hospitalised with heart failure has concluded that it provided a modest improvement in quality-of-life scores, as well as better clinical outcomes. It can be bewildering for heart failure patients to implement the advice of their doctors, says Pattern Health.

Hospitals 145

Hospitals 145

European Pharmaceutical Review

NOVEMBER 21, 2022

The first-in-human gene therapy trial for heart failure patients with preserved ejection fraction (HFpEF) has been approved by the US Food & Drug Administration (FDA). Heart failure with preserved ejection fraction. The syndrome accounts for half of all heart failure cases globally.

Labelling 128

Labelling 128

Express Pharma

APRIL 25, 2024

A press statement informed that Lyfe is now India’s first clinically proven remote cardiac rehabilitation program, designed to enhance heart health and quality of life. By providing tailored, accessible solutions in the comfort of patients’ homes, Lyfe empowers individuals to confidently manage their heart health.

94

94

pharmaphorum

APRIL 25, 2022

An analysis of 10 clinical trials of digital health interventions targeted at patients recently hospitalised for acute heart failure has found they improve outcomes compared to standard care. Patients in the digital arms also lost fewer days due to hospitalisation for heart failure – 1.77 with usual care to 8.5%

Hospitals 139

Hospitals 139

European Pharmaceutical Review

AUGUST 8, 2023

Tom Keith-Roach, President of AstraZeneca UK announced: “We are pleased that the SMC has now accepted Forxiga (dapagliflozin) for use in patients with chronic heart failure with preserved or mildly reduced ejection fraction and Tezspire (tezepelumab) has been accepted for restricted use in severe asthma within NHS Scotland.”

87

87

European Pharmaceutical Review

FEBRUARY 28, 2023

The largest cell therapy trial to date for chronic heart failure due to low ejection fraction (EF), has shown that mesenchymal precursor cells (MPCs) have potential for the first time to address inflammation. For the first time, we’ve discovered that stem cells can successfully treat the inflammation that causes heart failure.”

96

96

Pharmacy Times

OCTOBER 27, 2023

Sotagliflozin (Inpefa) is an orally administered dual SGLT1/2 inhibitor that reduces the risk of death due to heart failure.

26

26

pharmaphorum

SEPTEMBER 6, 2021

UK researchers have used artificial intelligence (AI) to develop a way to identify patients with heart failure who would benefit from treatment with beta blockers, by interrogating data from nine landmark clinical trials. The post AI could be used to guide drug therapy for heart failure appeared first on.

145

145

pharmaphorum

MARCH 3, 2022

Boehringer Ingelheim and Eli Lilly have published data for their SGLT2 inhibitor Jardiance in acute heart failure, setting them on course to position the drug across the spectrum of patients with the condition. The post Stage set for Jardiance to become universal heart failure drug appeared first on.

Labelling 98

Labelling Diabetes Hospitals 98

pharmaphorum

NOVEMBER 16, 2021

Moderna is already riding high on the strength of its mRNA-based COVID-19 vaccine, but the broader potential of its technology has been shown in a new AstraZeneca-partnered candidate for heart failure. As its name suggests, VEGF is a protein that stimulates formation of new blood vessels and repair of damaged heart muscle.

Vaccines 128

Vaccines Hospitals 128

European Pharmaceutical Review

FEBRUARY 7, 2023

Forxiga (dapagliflozin) has been approved in the European Union for heart failure (HF) with reduced ejection fraction (HFrEF) across the full spectrum of left ventricular ejection fraction (LVEF). AstraZeneca’s Forxiga is the first and only heart failure therapy with proven mortality benefit across the full ejection fraction range.

Diabetes 87

Diabetes 87

pharmaphorum

NOVEMBER 15, 2021

Johnson & Johnson’s SGLT2 inhibitor Invokana has been shown to have a significant effect on heart failure symptoms in a clinical trial that relied entirely on remote monitoring of symptoms using a smartphone app.

Diabetes 104

Diabetes Labelling 104

Pharmaceutical Technology

DECEMBER 20, 2023

Rexlemestrocel-L is under clinical development by Mesoblast and currently in Phase III for Congestive Heart Failure (Heart Failure).

40

40

pharmaphorum

FEBRUARY 25, 2022

Eli Lilly and Boehringer Ingelheim’s blockbuster diabetes drug Jardiance (empagliflozin) has been granted approval by the US Food and Drug Administration (FDA) for a wider range of heart failure patients. . According to the FDA, heart disease impacts more than 650,000 people in the US each year.

Diabetes 100

Diabetes 100

Pharmafile

FEBRUARY 8, 2023

Published date: 08/02/2023 Summary: • Data from GLPi animal studies demonstrate safety of second-generation DSRii product (DSR 2.0) • Data from Phase 1 study of DSR 2.0 in Mexico (CHIHUAHUA) and INDiii filing to US FDA expected in Q1 2023 • Planning to start MOJAVE, a US Phase 1/2a randomized controlled multi-center study of DSR 2.0,

72

72

Pharmaceutical Technology

DECEMBER 20, 2023

MYK-224 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Diastolic Heart Failure (HFpEF).

52

52

European Pharmaceutical Review

DECEMBER 12, 2022

The Medicines and Healthcare products Regulatory Agency ( MHRA ) has granted a licence extension for FORXIGA (dapagliflozin) in Great Britain for symptomatic chronic heart failure (HF) across the full spectrum of left ventricular ejection fraction (LVEF). Clinical trial data assessing dapagliflozin for chronic heart failure.

Diabetes 103

Diabetes 103

Pharmaceutical Technology

DECEMBER 20, 2023

Ferric carboxymaltose is under clinical development by Vifor Pharma Management and currently in Phase III for Congestive Heart Failure (Heart…

40

40

Pharmaceutical Technology

APRIL 14, 2023

ISX9-CPC is IPS HEART’s first patented drug candidate, and uses small molecule ISX-9 to reprogramme the iPSCs into new functional human heart muscle to treat heart failure and Duchenne cardiomyopathy. ISX9-CPC is expected to become the company’s first drug to be used clinically in humans.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98

pharmaphorum

JULY 2, 2021

AstraZeneca has reported the first phase 2 results with a drug for heart failure with preserved ejection fraction (HFpEF), showing it worked as expected but wasn’t able to provide any clinical benefit to patients. .

Labelling 98

Labelling 98

pharmaphorum

OCTOBER 16, 2020

Patients with heart failure often have a dismal prognosis as the condition usually worsens over time, but a new study aims to see if digital health technologies can improve their prospects. If it works, the approach could have a significant impact on the care of people with heart failure, which is a massive problem worldwide.

Communication 119

Communication Hospitals 119

Pharmaceutical Technology

SEPTEMBER 1, 2023

Bayer adds three new Phase III heart failure studies to the Kidney and type 2 diabetes drug, Kerendia, clinical development programme.

Labelling 52

Labelling Diabetes 52

Pharmaceutical Technology

SEPTEMBER 9, 2022

US-based biotech company Gatehouse Bio is extending its collaboration with AstraZeneca for developing RNA therapeutics to treat heart failure with preserved ejection fraction (HFpEF). The mutations were expected to regulate biological pathways that are related to a clinical syndrome.

Compounding 98

Compounding 98

Pharmacy Times

JANUARY 5, 2024

Conclusions could not be made regarding whether lower risk was associated with improvement in heart failure or if the success of optimal medications led to better clinical outcomes.

48

48

Pharmacy Joe

JUNE 7, 2023

In this episode, I’ll discuss torsemide vs furosemide for symptoms and quality of life among patients hospitalized for heart failure. Episode 824: Torsemide vs Furosemide – Which Is Better For Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure? appeared first on Pharmacy Joe.

Hospitals 59

Hospitals Inpatient Labelling 59

pharmaphorum

DECEMBER 24, 2020

Just a few weeks after its EU approval for heart failure, AstraZeneca’s Forxiga has been backed by NICE for this use by the NHS in England and Wales. AZ’s rivals Eli Lilly and Boehringer Ingelheim meanwhile are also attempting to develop their SGLT2 inhibitor Jardiance (empagliflozin) for heart failure.

Diabetes 98

Diabetes 98

Pharmaceutical Technology

MAY 10, 2023

The US Food and Drug Administration (FDA) has granted approval for AstraZeneca ’s Farxiga (dapagliflozin) to reduce the risks of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) emergency care visits in HF adult patients.

Diabetes 52

Diabetes 52